PETVIVO HOLDING, INC. ANNOUNCES DISTRIBUTION AGREEMENT WITH EQ ESPECIALIDADES
PetVivo Holdings (OTCQB: PETV) has signed a distribution agreement with Eq Especialidades to market and distribute Spryng™ with OsteoCushion™ technology throughout Mexico, effective April 1, 2025.
Spryng™ is an intra-articular injectable veterinary medical device containing sterilized, extra-cellular matrix microparticles. The technology works by adsorbing onto animal joint synovial lining and integrating with subsynovial tissue, helping restore proper joint mechanics. It aids in managing noninfectious joint pain conditions including joint instability, degenerative joint disease, and osteoarthritis.
This strategic partnership aims to expand PetVivo's presence in the Mexican animal health market, targeting both equine and companion animal segments.
PetVivo Holdings (OTCQB: PETV) ha firmato un accordo di distribuzione con Eq Especialidades per commercializzare e distribuire Spryng™ con tecnologia OsteoCushion™ in tutto il Messico, a partire dal 1° aprile 2025.
Spryng™ è un dispositivo medico veterinario iniettabile intra-articolare che contiene microparticelle di matrice extracellulare sterilizzate. La tecnologia agisce adsorbendosi sulla membrana sinoviale delle articolazioni degli animali e integrandosi con il tessuto subsinoviale, contribuendo a ripristinare il corretto funzionamento articolare. Aiuta a gestire condizioni di dolore articolare non infettive, tra cui instabilità articolare, malattia degenerativa delle articolazioni e osteoartrite.
Questa partnership strategica mira a espandere la presenza di PetVivo nel mercato messicano della salute animale, rivolgendosi sia al segmento equino che a quello degli animali da compagnia.
PetVivo Holdings (OTCQB: PETV) ha firmado un acuerdo de distribución con Eq Especialidades para comercializar y distribuir Spryng™ con tecnología OsteoCushion™ en todo México, a partir del 1 de abril de 2025.
Spryng™ es un dispositivo médico veterinario inyectable intraarticular que contiene micropartículas de matriz extracelular esterilizadas. La tecnología funciona adsorbiéndose en el revestimiento sinovial de las articulaciones de los animales e integrándose con el tejido subsinovial, ayudando a restaurar la mecánica articular adecuada. Ayuda a manejar condiciones de dolor articular no infecciosas, incluyendo inestabilidad articular, enfermedad articular degenerativa y osteoartritis.
Esta asociación estratégica tiene como objetivo ampliar la presencia de PetVivo en el mercado mexicano de salud animal, enfocándose en los segmentos equino y de animales de compañía.
PetVivo Holdings (OTCQB: PETV)는 Eq Especialidades와 2025년 4월 1일부터 멕시코 전역에 OsteoCushion™ 기술이 적용된 Spryng™을 마케팅 및 유통하는 배포 계약을 체결했습니다.
Spryng™은 멸균된 세포외 기질 미세입자를 포함하는 관절 내 주사형 수의학 의료기기입니다. 이 기술은 동물 관절의 활막에 흡착되어 활막하 조직과 통합되어 관절의 정상적인 기능 회복을 돕습니다. 감염성 관절염이 아닌 통증 상태, 관절 불안정성, 퇴행성 관절 질환 및 골관절염 관리에 도움을 줍니다.
이번 전략적 파트너십은 멕시코 동물 건강 시장에서 PetVivo의 입지를 확장하여 말과 반려동물 부문을 대상으로 합니다.
PetVivo Holdings (OTCQB : PETV) a signé un accord de distribution avec Eq Especialidades pour commercialiser et distribuer Spryng™ avec la technologie OsteoCushion™ à travers le Mexique, à compter du 1er avril 2025.
Spryng™ est un dispositif médical vétérinaire injectable intra-articulaire contenant des microparticules de matrice extracellulaire stérilisées. Cette technologie agit en s'adsorbant sur la membrane synoviale des articulations des animaux et en s'intégrant au tissu sous-synovial, aidant ainsi à restaurer la mécanique articulaire appropriée. Il aide à gérer les douleurs articulaires non infectieuses, y compris l'instabilité articulaire, les maladies articulaires dégénératives et l'arthrose.
Ce partenariat stratégique vise à étendre la présence de PetVivo sur le marché mexicain de la santé animale, ciblant à la fois les segments équin et des animaux de compagnie.
PetVivo Holdings (OTCQB: PETV) hat eine Vertriebsvereinbarung mit Eq Especialidades unterzeichnet, um Spryng™ mit OsteoCushion™-Technologie ab dem 1. April 2025 in ganz Mexiko zu vermarkten und zu vertreiben.
Spryng™ ist ein intraartikuläres injizierbares veterinärmedizinisches Gerät, das sterilisierte extrazelluläre Matrix-Mikropartikel enthält. Die Technologie wirkt, indem sie sich an die Synovialauskleidung von Tiergelenken anlagert und sich mit dem sub-synovialen Gewebe integriert, wodurch die richtige Gelenkmechanik wiederhergestellt wird. Es unterstützt die Behandlung nichtinfektiöser Gelenkschmerzen, einschließlich Gelenkinstabilität, degenerativer Gelenkerkrankungen und Osteoarthritis.
Diese strategische Partnerschaft zielt darauf ab, die Präsenz von PetVivo auf dem mexikanischen Tiergesundheitsmarkt auszubauen und sowohl den Pferde- als auch den Begleittiermarkt anzusprechen.
- Geographic expansion into Mexican market through established distributor
- Enhanced market access for Spryng™ product line
- Strategic partnership to increase product exposure and market penetration
- None.
MINNEAPOLIS, April 16, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW) ("PetVivo"), an emerging biomedical device company focused on the commercialization of innovative medical devices and other therapeutics for equine and companion animals, announced today it has entered into a definitive distribution agreement with Eq Especialidades (“Eq Especialidades”). Eq Especialidades will inventory, market and promote PetVivo’s veterinary medical device, Spryng™ with OsteoCushion™ technology, throughout Mexico. Eq Especialidades sales and marketing activities will commence on April 1, 2025.
SPRYNG® with OsteoCushion® Technology, is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
"We are incredibly pleased to add Eq Especialidades to our current distribution network to assist us in commercializing our signature product, Spryng with OsteoCushion technology, in Mexico. By adding Eq Especialidades to our current distribution network, they will assist PetVivo in achieving significant exposure to and penetration in the Mexican animal health market. We believe this new relationship will benefit the veterinary industry, the veterinarians who provide medical care to their patients, the animals receiving Spryng as well as the owners benefiting from the enhanced medical outcomes of their horses and companion animals," stated John Lai, Chief Executive Officer for PetVivo Holdings, Inc.
”For more information about PetVivo Holdings, Inc. please contact info1@petvivo.com or visit https://petvivo.com/ and https://www.sprynghealth.com.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCQB: PETV; OTCPINK: PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead products SPRYNG™ with OsteoCushion™ technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale.
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
Forward-Looking Statements:
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ
What is the new distribution agreement announced by PETV for Mexico?
How does PETV's Spryng™ technology work for joint treatment?
What medical conditions does PETV's Spryng™ treat in animals?
When will PETV's distribution partnership with Eq Especialidades begin operations?
